Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
about
An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritisPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesOld and new treatment targets in axial spondyloarthritisNon-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?Are patient-reported outcome instruments for ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysisNew treatment targets for axial spondyloarthritisAn evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapyShould axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Effectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology.Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis.Advances in managing ankylosing spondylitisThe efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials.Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trialEfficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysisSafety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis.The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis.Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritisDoes the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter studyScintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis.A psychometric analysis of outcome measures in peripheral spondyloarthritis.Inhibition of Complement Retards Ankylosing Spondylitis ProgressionImpact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis.Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Two-Year Follow-up Period in Recent-Onset Spondyloarthritis.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Active axial spondyloarthritis: potential role of certolizumab pegol.Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
P2860
Q26741170-4AEA62C3-C5BA-486E-AFA6-5C6CDA3B0F33Q26777084-1E0D2F72-AC70-4AB6-ABF9-021C8C24DA2DQ26777906-E00B642D-E54A-49FE-95CB-74AA74DF824DQ26777908-1BDFCC4E-0FB2-4BA0-B0FA-EA4F768D86CEQ26823664-321F434E-3487-4818-AFBE-5AD3CABE7436Q28073999-59BF615E-C05F-4A26-A65B-92564797B4B4Q28074393-EE455BCD-87FB-4F73-B524-977FDD076B82Q30239856-9DFCE210-2E58-4AAD-8EF4-DC3EB3B373C9Q30240183-872B09FA-6498-48C6-BBFC-4405C2D14AA4Q30240212-665A6723-B4A4-4122-9972-7E61EC87FC84Q30776497-F76F8EFA-7425-4020-8671-CF3F7ABF04F7Q33710428-236FB1A2-BF34-4A04-85CC-40EA5B1895BCQ33833623-4091A25D-8456-4E34-8B69-FCC057F271C9Q34201927-9E2AE63E-46E6-427A-8CFF-81F783A9ECC8Q34769757-DBC331F2-66D4-442E-AF2A-6C4C629F9681Q34808170-6D896B2D-4A1B-40A6-AC22-CBAC4117920AQ34818636-2B1B87C5-AB96-46CC-9B5E-7399E6099A17Q34894874-43F62D9C-3FC3-410E-9B29-62F0A71CDBDFQ35194568-AB19260F-1A7B-4167-9673-B8DBC7018DA6Q35608168-4D64CC83-FC55-4F2F-A1D0-628856D94D37Q35758262-FA224141-A7B2-4B41-93A5-6B4E6F602FE7Q36182383-A4CF9AE9-2737-490E-9F57-0901798F0494Q36183786-54D0E78F-802F-43BA-8EF5-F5203F7BB0E8Q36366162-1D14E7DE-4458-4DAB-B4EB-87E4CFDF9308Q36383550-823C390C-454A-4E97-965D-96250C841A38Q36477447-B94830A5-38A0-434B-99BB-60B9B96BB11DQ36584217-0D418810-071D-47D6-89B7-E4703B8475F2Q36715135-14DEB862-0866-46C1-A186-BD67D6E0B769Q36976429-717A0925-751B-4056-94DE-32F5A4E15C2CQ37063563-845DDC0A-722A-49AA-89B7-C3565638323BQ37085650-60ED9244-397D-44CA-A29F-AC9539F18DCDQ37307003-25AAB1E6-F2E5-4B51-A9ED-5EFD2E7A3372Q37320545-A032FECF-D0E5-4BCA-915B-7DB1E2F7E90EQ37453012-6A6B5B46-CFE4-45B4-A80F-69CF4CA1980DQ37456359-75A66A6A-2DB1-4C3F-B0B6-8881BB673EECQ37485709-8FDA635F-1C44-4771-BA89-3B26F6A11248Q38194547-34A918FA-9B94-4E58-B794-1B3A7C53F40DQ38198090-9D2AC8AF-433D-42D8-8CCF-6A5BCE24AB4EQ38199786-18F3E302-A7D4-4B83-861C-DDA87A8A745EQ38203474-C4DA8A62-5F90-4F8D-805F-2EBBEE21D904
P2860
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy of certolizumab pegol ...... cebo-controlled Phase 3 study.
@en
Efficacy of certolizumab pegol ...... cebo-controlled Phase 3 study.
@nl
type
label
Efficacy of certolizumab pegol ...... cebo-controlled Phase 3 study.
@en
Efficacy of certolizumab pegol ...... cebo-controlled Phase 3 study.
@nl
prefLabel
Efficacy of certolizumab pegol ...... cebo-controlled Phase 3 study.
@en
Efficacy of certolizumab pegol ...... cebo-controlled Phase 3 study.
@nl
P2093
P2860
P1476
Efficacy of certolizumab pegol ...... cebo-controlled Phase 3 study.
@en
P2093
A Fichtner
D van der Heijde
M Dougados
M Rudwaleit
P2860
P356
10.1136/ANNRHEUMDIS-2013-204231
P407
P577
2013-09-06T00:00:00Z